| 产品编号 | bs-6633R |
| 英文名称 | FOXL2 Rabbit pAb |
| 中文名称 | 叉头蛋白L2抗体 |
| 别 名 | blepharophimosis; Blepharophimosis epicanthus inversus and ptosis 1; Blepharophimosis epicanthus inversus and ptosis; BPES 1; BPES; BPES1; epicanthus inversus and ptosis 1; forkhead box L2; Forkhead box protein L2; forkhead transcription factor FOXL2; FOX L2; FOXL 2; FOXL2; FOXL2_HUMAN; PFRK; PINTO; POF 3; POF3. |
 |
Specific References (2) | bs-6633R has been referenced in 2 publications.
[IF=2.852] Cai et al. Molecular mechanisms of enhancing porcine granulosa cell proliferation and function by treatment in vitro with anti-inhibin alpha subunit antibody. (2015) Reprod.Biol.Endocrinol. 13:26 WB ; Porcine.
[IF=2.24] Liu, Xing-Long, et al. "FOXL2 suppresses proliferation, invasion and promotes apoptosis of cervical cancer cells."International Journal of Clinical and Experimental Pathology 7.4 (2014): 1534-1543. IHC-P ; Human.
|
| 研究领域 | 细胞生物 转录调节因子 |
| 抗体来源 | Rabbit |
| 克隆类型 | Polyclonal |
| 克 隆 号 | |
| 交叉反应 | Human,Mouse (predicted: Rat,Rabbit,Pig,Cow,Dog) |
| 产品应用 | WB=1:500-2000,IHC-P=1:100-500,IHC-F=1:100-500,IF=1:100-500
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 理论分子量 | 45-50 kDa |
| 检测分子量 | |
| 细胞定位 | 细胞核 |
| 性 状 | Liquid |
| 浓 度 | 1mg/ml |
| 免 疫 原 | KLH conjugated synthetic peptide derived from human FOXL2: 71-170/376 |
| 亚 型 | IgG |
| 纯化方法 | affinity purified by Protein A |
| 缓 冲 液 | 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| 保存条件 | Shipped at 4℃. Store at -20℃ for one year. Avoid repeated freeze/thaw cycles. |
| 注意事项 | This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
| PubMed | PubMed |
| 产品介绍 |
Transcriptional regulator. Critical factor essential for ovary differentiation and maintenance, and repression of the genetic program for somatic testis determination. Prevents trans-differentiation of ovary to testis throught transcriptional repression of the Sertoli cell-promoting gene SOX9 (By similarity). Has apoptotic activity in ovarian cells. Suppresses ESR1-mediated transcription of PTGS2/COX2 stimulated by tamoxifen (By similarity). Is a regulator of CYP19 expression (By similarity). Participates in SMAD3-dependent transcription of FST via the intronic SMAD-binding element (By similarity). Is a transcriptional repressor of STAR. Activates SIRT1 transcription under cellular stress conditions. Activates transcription of OSR2. Function: Transcriptional regulator. Critical factor essential for ovary differentiation and maintenance, and repression of the genetic program for somatic testis determination. Prevents trans-differentiation of ovary to testis throught transcriptional repression of the Sertoli cell-promoting gene SOX9 (By similarity). Has apoptotic activity in ovarian cells. Suppresses ESR1-mediated transcription of PTGS2/COX2 stimulated by tamoxifen (By similarity). Is a regulator of CYP19 expression (By similarity). Participates in SMAD3-dependent transcription of FST via the intronic SMAD-binding element (By similarity). Is a transcriptional repressor of STAR. Activates SIRT1 transcription under cellular stress conditions. Activates transcription of OSR2. Subunit: Interacts with ESR1 (By similarity). Interacts with SMAD3 (By similarity). Interacts with DDX20. Interacts with UBE2I/UBC9. Subcellular Location: Nucleus. Tissue Specificity: In addition to its expression in the developing eyelid, it is transcribed very early in somatic cells of the developing gonad (before sex determination) and its expression persists in the follicular cells of the adult ovary. Post-translational modifications: Sumoylated by SUMO1; sumoylation is required for transcriptional repression activity. DISEASE: Defects in FOXL2 are a cause of blepharophimosis, ptosis, and epicanthus inversus syndrome (BPES) [MIM:110100]; also known as blepharophimosis syndrome. It is an autosomal dominant disorder characterized by eyelid dysplasia, small palpebral fissures, drooping eyelids and a skin fold running inward and upward from the lower lid. In type I BPSE (BPES1) eyelid abnormalities are associated with female infertility. Affected females show an ovarian deficit due to primary amenorrhea or to premature ovarian failure (POF). In type II BPSE (BPES2) affected individuals show only the eyelid defects. There is a mutational hotspot in the region coding for the poly-Ala domain, since 30% of all mutations in the ORF lead to poly-Ala expansions, resulting mainly in BPES type II. Similarity: Contains 1 fork-head DNA-binding domain. SWISS: P58012.1 Gene ID: 668 Database links: Entrez Gene: 668 Human Entrez Gene: 26927 Mouse Omim: 605597 Human SwissProt: P58012 Human SwissProt: O88470 Mouse Unigene: 289292 Human Unigene: 151239 Mouse |
| 产品图片 |
Sample:
K562 Cell(Human)Lysate at 30 ug
Primary: Anti- FOXL2 (bs-6633R)at 1/300 dilution
Secondary: IRDye800CW Goat Anti-Rabbit IgG at 1/20000 dilution
Predicted band size: 45-50kD
Observed band size: 50kD
Sample:
A431 Cell (Human) Lysate at 30 ug
Primary: Anti- FOXL2 (bs-6633R)at 1/300 dilution
Secondary: IRDye800CW Goat Anti-Rabbit IgG at 1/20000 dilution
Predicted band size: 45-50kD
Observed band size: 45kD
Sample:
Lane 1: Human PANC-1 cell lysates
Lane 2: Human K562 cell lysates
Primary: Anti-FOXL2 (bs-6633R) at 1/1000 dilution
Secondary: IRDye800CW Goat Anti-Rabbit IgG at 1/20000 dilution
Predicted band size: 45-50 kDa
Observed band size: 55 kDa
Paraformaldehyde-fixed, paraffin embedded (mouse ovary tissue); Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15min; Block endogenous peroxidase by 3% hydrogen peroxide for 20 minutes; Blocking buffer (normal goat serum) at 37°C for 30min; Antibody incubation with (FOXL2) Polyclonal Antibody, Unconjugated (bs-6633R) at 1:400 overnight at 4°C, followed by operating according to SP Kit(Rabbit) (sp-0023) instructionsand DAB staining.
|
| 1、抗体溶解方法 | |
| 2、抗体修复方式 | |
| 3、常用试剂的配制 | |
| 4、免疫组化操作步骤 | |
| 5、免疫组化问题解答 | |
| 6、Western Blotting 操作步骤 | |
| 7、Western Blotting 问题解答 | |
| 8、关于肽链的设计 | |
| 9、多肽的溶解与保存 | |
| 10、酶标抗体效价测定程序 | |
